NervGen Pharma Corp. NGEN.V

Company Overview

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies for nervous system repair and neuroregeneration. The company operates in the biotechnology and pharmaceutical sectors, with a primary emphasis on treatments for spinal cord injury, neurodegenerative disorders, and other conditions involving damage to the central nervous system. NervGen’s lead therapeutic platform is based on research related to protein tyrosine phosphatase sigma (PTPσ), a receptor involved in inhibiting nerve regeneration after injury. The company trades on the TSX Venture Exchange under the symbol NGEN and on the OTCQX market in the United States.

The company’s principal revenue drivers are currently tied to research and development activities, strategic financing, and advancement of clinical-stage assets rather than commercial product sales. Its lead product candidate, NVG-291, is being evaluated for its potential to promote nerve regeneration and functional recovery following spinal cord injury and other neurological conditions. NervGen’s strategic positioning is linked to its proprietary intellectual property portfolio licensed from Case Western Reserve University, including foundational discoveries made by neuroscientist Dr. Jerry Silver. Founded in 2017 and headquartered in Vancouver, Canada, the company evolved through the acquisition and development of neuroregenerative technologies aimed at addressing areas of significant unmet medical need.

Business Operations

NervGen’s operations are primarily organized around drug discovery, preclinical development, and clinical advancement of regenerative therapeutics targeting the nervous system. The company’s central business unit is its neuroregeneration platform centered on PTPσ modulation. Its lead candidate, NVG-291, is designed to enhance neural repair by enabling nerve growth across inhibitory scar tissue that forms after injury. Revenue generation currently depends on equity financing, public market funding, and strategic capital raises typical of development-stage biotechnology firms, as the company has not yet commercialized any approved therapies.

Operationally, NervGen conducts research and clinical activities in both Canada and the United States, leveraging collaborations with contract research organizations, clinical trial centers, and academic institutions. The company controls intellectual property associated with its licensed technology platform and maintains development rights related to its regenerative peptide therapeutics. NervGen has worked with multiple clinical and scientific partners to advance clinical trials and regulatory activities, though publicly available disclosures do not identify major revenue-generating joint ventures or large-scale commercial partnerships as of recent filings. Data regarding material international subsidiaries beyond core operating entities is limited in public disclosures.

Strategic Position & Investments

NervGen’s strategic direction is centered on advancing NVG-291 through clinical development while expanding the therapeutic applications of its neuroregeneration platform. The company has prioritized indications with substantial unmet need, particularly spinal cord injury, where few restorative therapies currently exist. Management has indicated interest in evaluating broader neurological applications, including neurodegenerative diseases and peripheral nerve injury, subject to clinical validation and regulatory progress.

The company’s most significant strategic asset is its exclusive license to intellectual property originating from Case Western Reserve University tied to the work of Dr. Jerry Silver. NervGen has invested heavily in clinical trial execution, manufacturing scale-up, and translational neuroscience research to support future regulatory pathways. Public filings and investor materials also indicate ongoing investment in biomarker development, clinical infrastructure, and expanded scientific advisory capabilities. Data inconclusive based on available public sources regarding any major acquisitions or portfolio company investments beyond core therapeutic development activities.

Geographic Footprint

NervGen is headquartered in Vancouver, Canada, with operational and clinical activities extending into the United States. The company’s clinical development strategy relies heavily on North American research institutions, trial sites, and regulatory engagement with both Canadian and U.S. authorities, including interactions related to U.S. Food and Drug Administration clinical processes.

While NervGen does not currently maintain a broad commercial operating footprint across multiple continents, its scientific collaborations and investor base have international reach. The company’s shares are accessible to both Canadian and U.S. investors through public exchange listings, and its intellectual property and clinical research activities position it within the broader global biotechnology and neuroregeneration landscape. Publicly available information does not indicate substantial direct operational infrastructure outside North America.

Leadership & Governance

NervGen’s leadership team is composed of executives and directors with backgrounds in biotechnology development, pharmaceuticals, finance, and neuroscience. The company’s governance structure reflects a clinical-stage biotechnology focus emphasizing scientific advancement, regulatory development, and capital allocation discipline. Strategic leadership has consistently emphasized advancing regenerative medicine technologies through evidence-based clinical development and protection of proprietary intellectual property.

Key executives and leadership figures include:

• Paul Brennan – President and Chief Executive Officer
• Mike Kelly – Chief Financial Officer
• Daniel Mikol, M.D., Ph.D. – Chief Medical Officer
• Jerry Silver, Ph.D. – Scientific Founder
• John Reynolds – Chair of the Board

Company information, executive appointments, and operational disclosures are supported by publicly available materials including SEDAR+ filings, company investor presentations, and corporate releases. Clinical and strategic details are broadly consistent across public company disclosures and independent biotechnology reporting sources.